- Home
- ACIU vs MACI Comparison
ACIU vs MACI Comparison
Compare ACIU & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- MACI
- Stock Information
- Founded
- ACIU 2003
- MACI 2024
- Country
- ACIU Switzerland
- MACI United States
- Employees
- ACIU N/A
- MACI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- MACI
- Sector
- ACIU Health Care
- MACI
- Exchange
- ACIU Nasdaq
- MACI NYSE
- Market Cap
- ACIU 247.4M
- MACI 221.3M
- IPO Year
- ACIU 2016
- MACI 2024
- Fundamental
- Price
- ACIU $1.98
- MACI $10.23
- Analyst Decision
- ACIU Strong Buy
- MACI
- Analyst Count
- ACIU 2
- MACI 0
- Target Price
- ACIU $12.00
- MACI N/A
- AVG Volume (30 Days)
- ACIU 197.4K
- MACI 66.6K
- Earning Date
- ACIU 03-13-2025
- MACI 01-01-0001
- Dividend Yield
- ACIU N/A
- MACI N/A
- EPS Growth
- ACIU N/A
- MACI N/A
- EPS
- ACIU N/A
- MACI N/A
- Revenue
- ACIU $30,136,397.00
- MACI N/A
- Revenue This Year
- ACIU $120.91
- MACI N/A
- Revenue Next Year
- ACIU $13.82
- MACI N/A
- P/E Ratio
- ACIU N/A
- MACI $43.79
- Revenue Growth
- ACIU 84.51
- MACI N/A
- 52 Week Low
- ACIU $1.95
- MACI $9.95
- 52 Week High
- ACIU $4.98
- MACI $10.34
- Technical
- Relative Strength Index (RSI)
- ACIU 27.05
- MACI N/A
- Support Level
- ACIU $1.95
- MACI N/A
- Resistance Level
- ACIU $2.05
- MACI N/A
- Average True Range (ATR)
- ACIU 0.13
- MACI 0.00
- MACD
- ACIU -0.02
- MACI 0.00
- Stochastic Oscillator
- ACIU 6.38
- MACI 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.